10-K: Yubo International Biotech Limited Reports Form 10-K Filing for Fiscal Year Ended December 31, 2024

Yubo International Biotech Limited files its Form 10-K, reporting financial results for the fiscal year ended December 31, 2024, highlighting a net loss and discussing risks associated with its VIE structure and operations in China.

Summary

• Yubo International Biotech Limited, a U.S. holding company operating primarily through its Cayman Islands subsidiary, has filed its Form 10-K for the fiscal year ended December 31, 2024.
• The company operates in China through subsidiaries and contractual arrangements with a Variable Interest Entity (VIE), Yubo International Biotech (Beijing) Limited.
• The company reported sales of $3,470 for the year ended December 31, 2024, a significant decrease compared to $604,676 in 2023.
• The cost of goods sold also decreased to $822 in 2024 from $185,491 in 2023.
• The company's gross profit was $2,648 for 2024, substantially lower than the $419,185 reported in 2023.
• Operating expenses increased to $1,772,567 in 2024 from $1,613,891 in 2023, driven by increases in employee compensation and other operating expenses.
• The company's net loss increased to $1,981,792 for 2024, compared to $1,195,083 in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $7,015 and a negative working capital of $4,038,998.
• The company has received a financial support letter from its largest shareholder, Jun Wang, to enable it to meet its liabilities for the next 12 months.
• The company's auditor has included an explanatory paragraph in the audit report expressing substantial doubt about the company's ability to continue as a going concern.
• The company is subject to risks associated with its VIE structure and the complex regulatory environment in China.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant losses, a decrease in sales, and concerns about the company's ability to continue as a going concern. However, the financial support letter from the largest shareholder provides some reassurance.

Positives

• The company has received a financial support letter from its largest shareholder, Jun Wang, to enable it to meet its liabilities for the next 12 months.
• The company is taking steps to obtain new sources of financing and may raise additional capital in 2025.

Negatives

• The company experienced a significant decrease in sales, from $604,676 in 2023 to $3,470 in 2024.
• The company's net loss increased to $1,981,792 for 2024, compared to $1,195,083 in the previous year.
• The company has a negative working capital of $4,038,998 as of December 31, 2024.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company relies on a small number of customers for a significant percentage of its revenue.

Risks

• The company's VIE structure and operations in China are subject to complex and evolving PRC laws and regulations.
• Changes in China's economic, political, or social conditions could materially and adversely affect the company's business.
• The company's business might be subject to various evolving PRC laws and regulations regarding cybersecurity, data privacy, and data security.
• The company may need additional capital and may not be able to obtain it on acceptable terms or at all.
• The commercial success of the company's products depends upon the degree of their market acceptance among the medical community.

Future Outlook

The company plans to obtain new sources of financing and may raise additional capital in 2025 to continue as a going concern.

Industry Context

The company operates in the highly regulated and competitive medical industry in China, facing competition from both domestic and international players.

Comparison to Industry Standards

• The document mentions VCANBIO CELL&GENE (SHA: 600645) as a key competitor, with revenue of approximately RMB1.2 billion in the first three quarters of 2024.
• This provides a benchmark for comparing Yubo International Biotech's performance against a larger, established player in the cell preparation and storage market.

Related Party Transactions

• As of December 31, 2024, we had payables due to Mr. Yang Wang in the amount of $434,764 and Mr. Jun Wang in the amount of $2,293,341.
• As of December 31, 2024, we also had payables due to Mr. Huang Li and Mr. Jin Wei, each an indirect shareholder, in the amount of $53,430 and $30,000, respectively.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity securities.
• The company's ability to pay dividends is restricted by PRC laws and regulations.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern, which could impact stakeholders.

Next Steps

• The company intends to continue working toward identifying and obtaining new sources of financing.
• The company may raise additional capital in 2025.

Key Dates

Keywords

Yubo International Biotech, Form 10-K, financial results, VIE structure, China operations, going concern, stem cell, biotech